- The IIBM held the first edition of Brain Breaking Bad, a meeting that brought together cutting-edge research in neuro-oncology with patient associations and society, and that gathered more than 140 participants
The Gabriella Morreale Auditorium of the Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM), CSIC-UAM, was the venue for the first edition of Brain Breaking Bad, dedicated to brain tumors and metastases in the central nervous system. The event, organized by the Neurological Diseases and Cancer scientific programs of the IIBM, brought together clinical and basic researchers, patients, family members, and representatives of foundations, exceeding expectations for attendance.
The event also enjoyed the support and presence of high-ranking institutional representatives from the CSIC and the Universidad Autónoma de Madrid (UAM). The opening ceremony was led by Pilar López Larrubia, Director of the IIBM, accompanied by María de los Ángeles Martín Cabrejas, Vice-Rector for Scientific Policy of the UAM, and Elena Cartea González, Deputy Vice President for Scientific and Technical Areas of the CSIC.
The scientific program showcased recent advances in the understanding of primary brain tumors such as glioma and glioblastoma, as well as brain metastases originating from other cancers (including melanoma and breast cancer). Researchers presented novel mechanisms of tumor-microenvironment interaction, innovative therapeutic strategies based on polypeptides capable of crossing the blood-brain barrier, and the potential of cannabinoids and other molecular targets. A strong emphasis was placed on the translational potential of these findings, with the shared goal of accelerating their journey from the laboratory to the clinic to achieve tangible improvements in patient outcomes.
The voice of patients and foundations: a key driver for change
One of the most outstanding moments of the day was the participation of four patient associations (ALMIA, Fundación Blanca Morell, Fundación Martín Álvarez Muelas, and ASATE). Their presence highlighted the critical importance of integrating the patient and family perspective into the research process. Representatives shared their experiences and needs, with special attention to access to new treatments and clinical trials. This direct dialogue between scientists and patients reinforced the commitment to orient research towards the real priorities of those living with the disease, ensuring that scientific progress translates into meaningful impact and hope for the affected community.
Promising avenues in primary brain tumors
The third session, dedicated to primary brain tumors, delved into the molecular biology of these aggressive diseases and explored new therapeutic avenues, including innovative immunotherapy approaches and real-time imaging techniques to better understand tumor invasion dynamics in pediatric gliomas. All presentations underscored the urgent need to translate biological knowledge into clinical applications that improve survival and quality of life.
The event concluded with a round table titled "Patients, Science, and Society: A Shared Journey".
With this first edition, the IIBM reaffirms its commitment to fostering collaborative spaces where scientific excellence meets the real needs of patients, paving the way for a future in which brain tumors become a treatable and ultimately curable disease.